[Sponsored] Mobile clinics are expanding access to care by helping health care organizations deliver services directly to communities.

The post Top Companies to Build and Operate Mobile Clinics for Your Organization appeared first on MedCity News.

At Wayne General Hospital in rural Mississippi, clinicians are using Eko Health’s AI-powered digital stethoscope to detect heart conditions earlier in patients with limited access to specialists.

The post How A Small Rural Hospital Is Using AI to Catch Heart Disease Sooner appeared first on MedCity News.

Cardiology, in particular, offers a clear view into why so many AI solutions struggle to scale and what differentiates those that are poised for adoption.

The post The Real Test for AI Diagnostics Isn’t Performance — It’s Clinical Adoption appeared first on MedCity News.

Danaher is acquiring Masimo in a $10 billion deal aimed at expanding its diagnostics portfolio and deepening its presence in acute care settings. The move reflects a broader industry shift toward consolidation and integrated care, as large healthcare companies seek scale and more continuous clinical data inside hospitals.

The post Danaher Drops $10B to Snatch Masimo in Diagnostics Push appeared first on MedCity News.

Speed still matters, but there’s been a shift in the industry. It’s not enough to be scientifically sound. Now, practicality is of utmost importance.

The post From Pandemic Urgency to Practical Impact: How Diagnostics Investment Priorities Are Evolving appeared first on MedCity News.

Samsung launched a new ultrasound system at this year’s RSNA conference. The system, called the R20, is designed to reduce user variability through real-time guidance, as well as provide AI-powered diagnostic support.

The post Samsung’s New Ultrasound System Wants to Make Every Scan Consistent appeared first on MedCity News.

This week, CMS established a reimbursement code for Eko Health’s AI platform, which seeks to aid clinicians in the diagnosis of heart conditions. The goal behind the technology is to help catch heart disease earlier, when it’s easier to treat, and to make high quality diagnostic care more accessible.

The post Eko Health’s AI for Cardiac Diagnoses Earns CMS Reimbursement Rate appeared first on MedCity News.

Fujirebio Diagnostics’ blood test for Alzheimer’s disease offers a less expensive and less invasive alternative compared to medical imaging and tests of cerebrospinal fluid. But competition looms from blood-based tests in development by other diagnostics companies.

The post Alzheimer’s Disease Now Has Its First FDA-Cleared Blood Test appeared first on MedCity News.

[Sponsored] A webinar scheduled for Thursday May 8 at 1 pm ET sponsored by Mercury will explore how early-stage medtech and biopharma investors are looking at the market and how they’re advising startups in the wake of cuts to NIH and SBIR grants.

The post Get a Snapshot of the Early Stage Life Science Startup Landscape appeared first on MedCity News.

[Sponsored] Scheduled for May 8 at 1 pm ET, the conversation will include Morgan Cheatham, head of healthcare and life sciences at Breyer Capital, Gurdane Bhutani, founder and managing partner of MBX Capital, and will be moderated by Mercury Head of Healthcare and Life Sciences Ben Kromnick.

The post What Do Early Stage Life Science Companies Need to Grow? appeared first on MedCity News.

[Sponsored] A webinar on May 8th will explore how a banking platform approach could be a resource for the needs of entrepreneurs across biotech, diagnostics, and other life science companies.

The post How Can Fintech Make it Easier for Early Stage Life Science Companies to Grow? appeared first on MedCity News.

The FDA granted marketing authorization to a Visby Medical at-home PCR test for three common sexually transmitted infections. The Visby test yields results in about 30 minutes.

The post PCR Comes to the Home With FDA Authorization of Visby’s OTC Sexual Health Test appeared first on MedCity News.

Labcorp’s latest acquisition brings the oncology testing business of BioReference Health. Opko Health, BioReference’s parent, has been cutting costs to return to profitability.

The post Labcorp Is Buying BioReference Health’s Cancer Testing Business for $192M appeared first on MedCity News.

Infectious disease is the focus of the biopharma track at INVEST Pitch Perfect May 20-21 in Chicago. Register today!

The post A Snapshot of Five Contenders to Combat Infectious Diseases in the Post-Pandemic Landscape appeared first on MedCity News.

Inspired by the speed and ease of at-home Covid-19 tests, OncoSwab is developing a test for lung cancer that detects signs of the disease from a nasal swab. The test could become an alternative to the medical imaging currently used to screen for lung cancer.

The post Startup OncoSwab Aims to Make Lung Cancer Detection as Simple as Flu & Covid-19 Tests appeared first on MedCity News.

Months after 23andMe CEO Anne Wojcicki publicly stated she wants to take the company she co-founded private, all of the company’s independent board directors have resigned. The board letter to Wojcicki stated that its members preferred resigning over continuing to have a difference of view over the direction of the company.

The post Mass Board Exodus at 23andMe Leaves Company With Tough Decisions Ahead appeared first on MedCity News.

Check out news from Oral Genome, BeMe Health, Noetik, and Vouched.

The post StartUPDATES: New Developments from Healthcare Startups appeared first on MedCity News.

Function Health, a membership-based platform that gives consumers access to more than 100 different lab tests, closed a Series A financing round that brought its total funding to date to $53 million. The round was led by Andreessen Horowitz and included a slew of celebrity investors, including Matt Damon, Zac Efron, Blake Griffin and Colin Kaepernick.

The post Meet The Startup That Gives Consumers Access to 100+ Lab Tests For $500 Per Year appeared first on MedCity News.

Geneoscopy received approval for its noninvasive colorectal cancer screening test, which the FDA designated as a breakthrough device. This marks only the second time the FDA has issued an approval for a molecular diagnostic test for colorectal cancer — and the first time the agency has done so for a colorectal cancer test that uses RNA.

The post FDA Grants First-Ever Approval to an RNA-Based Diagnostic for Colorectal Cancer appeared first on MedCity News.

Labcorp is buying the clinical diagnostics and reproductive women’s health businesses of BioReference Health, excluding those assets in New York and New Jersey. Labcorp has returned to being fully focused on lab testing after last year’s spinoff of Fortrea, its former clinical trial services business.

The post Labcorp’s $237M Tuck-In Deal Brings Lab Testing Assets From BioReference Health appeared first on MedCity News.

Equal parts networking and curated panels covering the latest trends in healthcare investment, MedCity INVEST 2024 is the ideal event to discuss health tech, biopharma, devices and diagnostics investment opportunities. Register today!

The post Connect With More Than 50 Healthcare Startups at MedCity INVEST 2024! appeared first on MedCity News.

Each track will spotlight a different specialty area including: oncology, cardiology, women’s health and preventing burnout/supporting operational efficiency.

The post MedCity News is Accepting Applications for the Healthcare Startup Pitch Perfect Contest in Chicago appeared first on MedCity News.

The FDA awarded marketing authorization for a new Invitae test that uses next-generation sequencing to assess multiple genes to identify variants indicating a person’s predisposition for certain cancers. The regulatory action creates a new regulatory classification making Invitae’s test the predicate device for future cancer tests.

The post Invitae’s First of Its Kind Cancer Test Receives FDA Marketing Authorization appeared first on MedCity News.

Standard newborn screening can detect dozens of inherited diseases, but genomics technology enables testing for hundreds of them. A North Carolina program evaluating the feasibility of bringing genomics to newborn screening is expanding with an initial goal of testing 5,000 babies in the next year.

The post How Genome Sequencing Can Broaden the Scope of Newborn Screening appeared first on MedCity News.

[Sponsored] The Covid-19 pandemic changed the way we think of the role of diagnostics not only for clinicians but also consumers. The pandemic propelled innovation of in vitro diagnostics and the at-home test kits space for chronic conditions, sexual health, and more.

The post Diagnostic Testing Landscape Paves the Way for Consumer Centric Approach to Disease Detection appeared first on MedCity News.

Illumina must pay a €432 million fine for closing its Grail acquisition before the European Commission finished its inquiry into the tie-up. The penalty is the maximum amount the regulator can impose on a company for breaching European merger rules.

The post Europe Imposes Maximum Fine on Illumina for Early Grail Acquisition appeared first on MedCity News.

Yaniv Sneor, the co-founder of Mid Atlantic Bio Angels and part of the Ask the Investor sessions at MedCity INVEST this week, explained what his firm looks for in life science startups.

The post MedCity INVEST Ask the Investor Spotlight: Yaniv Sneor of Mid Atlantic Bio Angels appeared first on MedCity News.

Function Oncology goes beyond next-generation sequencing with a CRISPR-based technology that identifies targets for a patient’s cancer regardless of whether or not they are mutated. Now out of stealth, the company will present data validating its approach during the American Association for Cancer Research annual meeting.

The post Startup Function Oncology Aims to Make CRISPR Part of Next Revolution in Cancer appeared first on MedCity News.

The Federal Trade Commission has ordered Illumina to divest Grail, the liquid biopsy company it acquired for more than $7 billion. The agency said Illumina’s proposed remedies are insufficient and the tie-up is likely to reduce competition in the R&D and commercialization of new cancer tests.

The post FTC Orders Illumina to Divest Grail, Says Deal Stifles Cancer Test Competition appeared first on MedCity News.

[Sponsored] Hear from healthcare executives such as Nicholas Turos, vice president of business development with Babson Diagnostics, Marcus Perez, Altera Digital Health president, and Integra Connect COO Cory Wiegert on how they are meeting the challenges of healthcare innovation.

The post The Vibe at ViVE: A Progress Report on Healthcare Transformation appeared first on MedCity News.